CoChat

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

BRAF V600E is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting “active” protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer. Therefore, we pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular. By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered. PLX4720, a 7-azaindole derivative that inhibits B-Raf V600E with an IC 50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays. PLX4720 preferentially inhibits the active B-Raf V600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele. Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-Raf V600E -bearing tumor cell lines but not in cells lacking oncogenic B-Raf. In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf V600E -positive cells. In B-Raf V600E -dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity. The work described here represents the entire discovery process, from initial identification through structural and biological studies in animal models to a promising therapeutic for testing in cancer patients bearing B-Raf V600E -driven tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0711741105

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 1,346

Metadata

Authors
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S. M., Fong, D., Zhu, Y.-L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S.-H., Schlessinger, J., Zhang, K. Y. J., West, B. L., Powell, B., Habets, G., Zhang, C., Ibrahim, P. N., Hirth, P., Artis, D. R., Herlyn, M., & Bollag, G.
Affiliations
  • Plexxikon (United States) (US)
  • The Wistar Institute (US)
  • *Plexxikon, Inc., 91 Bolivar Drive, Berkeley, CA 94710;
  • University of California, Berkeley (US)
  • Yale University (US)
Venue
Proceedings of the National Academy of Sciences
Published
2008-02-26
Volume
105
Issue
8
Pages
3041-3046
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2154196978
Cited by
1,346
References
28
Citations by year
2026: 25 · 2025: 31 · 2024: 45 · 2023: 54 · 2022: 40 · 2021: 62 · 2020: 76 · 2019: 62 · 2018: 64 · 2017: 61 · 2016: 86 · 2015: 93 · 2014: 111 · 2013: 134 · 2012: 124
FWCI
39.03
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Energy (DE-AC03-76SF00515, DE-AC03-?, AC03-76SF00098, DEAC03-76SF00098, 76SF00515)
  • National Institutes of Health (DE-AC03- 76SF00098)
  • National Cancer Institute (R01CA047159, CA 47159, CA 880999, T32CA009171)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051448, AR 051886, P50 AR0504086, R01AR051886, AR051448)
  • Basic Energy Sciences (DE-AC03-76SF-00098, AC03-76SF00098, 76SF00515)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
BRAF V600E mutation, PLX4720, 7-azaindole, selective kinase inhibitors, melanoma, ERK1/2 phosphorylation, cell cycle arrest, apoptosis, tumor xenografts, structure-based drug design, oral anticancer therapy
MeSH terms
Animals, Cell Cycle, Escherichia coli, Humans, Indoles, Melanoma, Models, Molecular, Oncogenes, Phosphorylation, Sulfonamides, Molecular Structure, Mice, SCID, Apoptosis, Inhibitory Concentration 50, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. https://app.cochat.ai/papers/10.1073/pnas.0711741105
The paper
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S. M., Fong, D., Zhu, Y.-L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., . . . Bollag, G. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0711741105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.